Advancing Next Generation of Antibody-based therapeutics

Product Development Pipeline

Candidate Lead Discovery Pharmacology Preclinical Clinical
IGN001
Her2
   
IGN002
CD20
IND filling projected - Q1 2014
IGN003
Multiple Myeloma
   

IGN002:

Our lead candidate, IGN002, comprises an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system. CD20 is expressed on Non-Hodgkin lymphoma and other B cell driven hematologic malignancies. We have generated substantial preclinical data with IGN002, including data demonstrating that the targeting ability of IGN002 results in up to 100-fold higher than non-targeted IFN. Further, IGN002 also shows remarkable efficacy in rituximab resistant tumor models. These preclinical data demonstrate that IGN002 effectively targets and acts locally CD20- positive tumors.

IGN001:

Our second candidate, IGN001, comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system. Her2 is expressed on breast cancer and other malignancies. We are in early stages of generating preclinical data with IGN001.

IGN003:

Our IGN003 candidate comprises an monoclonal antibody directed towards a well validated Multiple Myeloma target attached to IFN through stable peptide linker system. We are in early stages of generating preclinical data with IGN003.